Mexico Gabriela Báez, Chief Commercial Officer of Up Pharma, elaborates on the company’s unique business model that supports small to medium sized pharmaceutical and preventative health companies in entering the Mexican market. In terms of your portfolio, what is the breakdown of your services and where do see the most growth?…
Mexico Dominik Bacher, founder and CEO at Bacher Zoppi, explains the latest changes in the commercialization stage of the healthcare industry and showcases the value proposition of Bacher Zoppi to successfully implement sustainable sales strategies. After slowing in 2012-13, Mexico’s pharmaceutical sector is expected to grow on average 5.6 percent rising…
Ireland David Adlam, Regional Manager of Ireland and South West UK, and Paul Morris, Strategic Account Manager for Life Sciences at Agility, discuss the company’s increased commitment to Ireland, their ongoing and successful efforts to expand their portfolio of life science clients as well as their focus on niche product areas.…
Switzerland Susanne Hoeppner, GM of Astellas Switzerland and board member of vips, discusses her key priorities, the culture of Swiss pharma, and the industry-wide push for faster approval times. Ms. Hoeppner, in addition to your role as general manager of Astellas, we understand you also have leadership role within the industry…
Mexico In charge of transforming the Monterrey-based family business of dermatological distribution into a Mexican corporate success story, Carlos de Kruyff, shares some of his most pertinent insights on the industry. He speaks about the company’s history and innovative commercialization scheme, the transformative regulatory landscape today, as well as their role…
Switzerland Diabetes is well managed in Switzerland’s patient-centric healthcare system, yet with new data showing Novo Nordisk’s GLP-1 has strong cardiovascular benefits, the company is working to drive a change in treatment standards. Switzerland has been recognized as the most innovative country in the world, and is known to have a…
Ipsen These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products. “Sales from [Somatuline® (lanreotide) and Decapeptyl® (triptorelin)] amounted to over EUR 700 million in 2015, which was over half of Ipsen’s global…
Switzerland The Chief Scientific Officer and President of Glenmark Pharmaceuticals Swiss R&D Center elaborates on Glenmark’s endeavor to venture up the pharmaceutical value chain and discusses the company’s R&D strategy. Furthermore, he highlights the significance of strategic partnerships in today’s pharmaceutical R&D efforts. You have spent 23 years working in large…
Mexico Aimed to ignite a paradigm shift away from the current traditional distributor model, Salumedic’s Managing Director, Gabriel Tagle, shares the novel business concept with zeal and sharp business acumen. He speaks about Saludemic’s core value preposition of being a “commercial hand” to key healthcare players, the crucial importance of proper…
Switzerland The managing director of Stallergenes Greer Switzerland, Claude Fischlewitz, explains how he has gone about revitalizing the company’s presence in Switzerland, while expressing his ambitions to restore and firmly position Stallergenes Greer as the number one provider of total allergy management in the country. Can you please start by providing…
Taiwan Wang Yu Pei, general manager of Nang Kuang Pharmaceutical, Taiwan’s indisputable market leader for injectable products, provides insights into the global ambitions of the company as Nang Kuang is about to bring its first injectable into the US market and is also looking for Europe-based partners to distribute its high-quality…
Switzerland “Get it done! That is what CARBOGEN AMCIS is all about!” – The CEO of the Swiss drug development and commercialization services company elaborates on the company’s strong mindset and declares customer intimacy to be their unique selling point. CARBOGEN AMCIS celebrated its 10th year since joining the Dishman group.…
See our Cookie Privacy Policy Here